Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 5/20 | 0.60 |
| ▸ | XDH | P47989 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131585 | 0.80 | QPCT (1.00) | QPCTKMT2AMPOXDHALDH1A1 | |
| SCHEMBL5127461 | 0.80 | QPCT (1.00) | QPCTKMT2AALDH1A1 | |
| SCHEMBL12713432 | 0.79 | MPO (0.73) | QPCTKMT2AMPOXDHALDH1A1 | |
| SCHEMBL5119605 | 0.78 | QPCT (1.00) | QPCTKMT2AALDH1A1 | |
| SCHEMBL3641679 | 0.78 | QPCT (1.00) | QPCTKMT2AMPOXDHALDH1A1 | |
| SCHEMBL5131052 | 0.77 | QPCT (1.00) | QPCTKMT2AALDH1A1 | |
| SCHEMBL7648079 | 0.76 | ALDH1A1 (0.74) | QPCTKMT2AMPOXDHALDH1A1 | |
| SCHEMBL3637547 | 0.76 | QPCT (1.00) | QPCTALDH1A1 | |
| SCHEMBL2731546 | 0.75 | MPO (1.00) | MPOXDHALDH1A1HAVCR2 | |
| SCHEMBL10288918 | 0.75 | MPO (0.68) | QPCTKMT2AMPOXDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | claimed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | claimed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2160389-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-03-10 | — | — | EP | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128982-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128982-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885KMT2A 3055/4885MPO 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.